SCHEMBL6503207

SCHEMBL6503207

O=S(=O)(Cl)c1ccc(Sc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
HSD17B10 Q99714 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
MMP13 P45452 7/20 0.51
MMP8 P22894 4/20 0.51
MMP3 P08254 2/20 0.51
HPGD P15428 1/20 0.44
MMP2 P08253 2/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
MMP1 P03956 1/20 0.42
ANXA2 P07355 1/20 0.42
S100A10 P60903 1/20 0.42
BCL2 P10415 1/20 0.41
MCL1 Q07820 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8779793 0.91 ALDH1A1 (0.52) ALDH1A1HSD17B10TDP1MMP13MMP8
SCHEMBL7607930 0.84 ALDH1A1 (0.46) ALDH1A1HSD17B10TDP1MMP13MMP8
Diphenylsulfane SCHEMBL9617662 0.84 ALDH1A1 (0.48) ALDH1A1HSD17B10TDP1MMP13MMP8
SCHEMBL10608103 0.82 HTR6 (0.59) ALDH1A1MMP13MMP8MMP3HPGD
SCHEMBL10608105 0.82 HTR6 (0.59) ALDH1A1MMP13MMP8MMP3HPGD
SCHEMBL10948877 0.82 HTR6 (0.59) ALDH1A1MMP13MMP8MMP3HPGD
SCHEMBL9625568 0.80 HTR6 (0.64) ALDH1A1MMP13MMP8MMP3HPGD
SCHEMBL1890274 0.80 MMP13 (0.53) ALDH1A1MMP13MMP8MMP3HPGD
Hydrochloric Acid SCHEMBL7353403 0.79 DDAH1 (0.56) ALDH1A1HSD17B10TDP1MMP13MMP8
SCHEMBL8779845 0.78 MMP13 (0.51) ALDH1A1MMP13MMP8MMP3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595243-B2 Modulators of extracellular signal-regulated kinase GEN1E LIFESCIENCES INC. (US) 2026-04-07 US disclosed
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. 2025-05-01 US disclosed
WO-2025085745-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE GEN1E LIFESCIENCES INC. (US) 2025-04-24 WO disclosed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 US disclosed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 US disclosed
WO-2005040112-A1 COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY OXAGEN LIMITED (GB) 2005-05-06 WO disclosed
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
EP-0770599-B1 PROCESS FOR THE PREPARATION OF AROMATIC OR HETEROAROMATIC SULFONYL HALIDES SUMITOMO SEIKA CHEMICALS (JP) 2002-08-07 EP disclosed
CN-1075058-C Process for preparation of aromatic or heteroaromatic sulfonyl halides SUMITOMO SEIKA CHEMICALS (JP) 2001-11-21 CN disclosed
US-5811571-A HALOGENATING AN AROMATIC OR HETEROAROMATIC METHYL SULFIDE OR METHYL SULFOXIDE IN PRESENCE OF WATER SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1998-09-22 US disclosed
CN-1150796-A Process for preparation of aromatic or heteroaromatic sulfonyl halides SUMITOMO SEIKA CHEMICALS (JP) 1997-05-28 CN disclosed
EP-0770599-A1 PROCESS FOR THE PREPARATION OF AROMATIC OR HETEROAROMATIC SULFONYL HALIDES SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1997-05-02 EP disclosed
US-4041051-A 1-AMINO-4-HYDROXY-2-(P-METHOXY OR ETHOXY-BENZENESULFONYLOXY)-ANTHRAQUINONE SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-08-09 US disclosed
US-3983300-A POLYAROMATIC SULFONE IMPERIAL CHEMICAL INDUSTRIES LIMITED (EN) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, ACE2 ALDH1A1 1858/4885HSD17B10 827/4885TDP1 2946/4885
US-20250136571-A1 MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE MAP3K20, MAP3K6, CDC42BPG ALDH1A1 4211/4885HSD17B10 4563/4885TDP1 3395/4885
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS MMP9, MMP2, MMP3 ALDH1A1 249/4885HSD17B10 661/4885TDP1 1699/4885
US-12595243-B2 Modulators of extracellular signal-regulated kinase CDC42BPG, GRK3, ERBB2 ALDH1A1 2876/4885HSD17B10 2235/4885TDP1 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.